PT1538202E - Produção de alga-galactosidase a humana - Google Patents

Produção de alga-galactosidase a humana Download PDF

Info

Publication number
PT1538202E
PT1538202E PT40301079T PT04030107T PT1538202E PT 1538202 E PT1538202 E PT 1538202E PT 40301079 T PT40301079 T PT 40301079T PT 04030107 T PT04030107 T PT 04030107T PT 1538202 E PT1538202 E PT 1538202E
Authority
PT
Portugal
Prior art keywords
galactosidase
production
human alpha
sample
gal
Prior art date
Application number
PT40301079T
Other languages
English (en)
Inventor
Douglas A Treco
Richard F Selden
Melanie D Williams
Marianne Borowski
Frances P Gillespie
Carol M Kinoshita
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of PT1538202E publication Critical patent/PT1538202E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
PT40301079T 1996-09-13 1997-09-12 Produção de alga-galactosidase a humana PT1538202E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71261496A 1996-09-13 1996-09-13

Publications (1)

Publication Number Publication Date
PT1538202E true PT1538202E (pt) 2014-04-22

Family

ID=24862863

Family Applications (1)

Application Number Title Priority Date Filing Date
PT40301079T PT1538202E (pt) 1996-09-13 1997-09-12 Produção de alga-galactosidase a humana

Country Status (21)

Country Link
EP (4) EP1538202B1 (pt)
JP (7) JP4001925B2 (pt)
KR (2) KR100547402B1 (pt)
CN (1) CN1268741C (pt)
AT (1) ATE286120T1 (pt)
AU (1) AU4424497A (pt)
CA (1) CA2265464C (pt)
DE (1) DE69732129T2 (pt)
DK (2) DK1538202T3 (pt)
ES (3) ES2458292T3 (pt)
HK (3) HK1022173A1 (pt)
HU (2) HU230275B1 (pt)
IL (2) IL128960A (pt)
MX (1) MX340738B (pt)
NO (4) NO328443B1 (pt)
NZ (2) NZ334721A (pt)
PL (1) PL190041B1 (pt)
PT (1) PT1538202E (pt)
RU (1) RU2179034C2 (pt)
TW (1) TW585919B (pt)
WO (1) WO1998011206A2 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
WO2000009153A1 (en) * 1997-10-29 2000-02-24 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
EP1658857A1 (en) * 1997-10-29 2006-05-24 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
AU2016250357B2 (en) * 1999-03-11 2018-11-01 Shire Human Genetic Therapies, Inc. Treatment of alpha-Galactosidase A deficiency
AU2012241170B2 (en) * 1999-03-11 2016-07-28 Shire Human Genetic Therapies, Inc. Treatment of alpha-Galactosidase A deficiency
AU2004242550B2 (en) * 1999-03-11 2008-04-03 Shire Human Genetic Therapies, Inc. Treatment of alpha-Galactosidase A deficiency
WO2002064799A2 (en) 1999-09-28 2002-08-22 Transkaryotic Therapies, Inc. Optimized messenger rna
EP2275559A3 (en) * 1999-09-28 2011-03-23 Shire Human Genetic Therapies, Inc. Optimized messenger RNA
AU1647501A (en) 1999-12-10 2001-06-18 Cytos Biotechnology Ag Replicon based activation of endogenous genes
CA2398995C (en) 2000-02-04 2014-09-23 Children's Hospital Research Foundation Lipid hydrolysis therapy for atherosclerosis and related diseases
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) * 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
AU2003228722B2 (en) 2002-04-25 2009-06-25 Takeda Pharmaceutical Company Limited Treatment of alpha-galactosidase A deficiency
EP1587923B1 (en) * 2003-01-22 2011-08-24 Duke University Improved constructs for expressing lysosomal polypeptides
US7935336B2 (en) 2005-11-18 2011-05-03 Tokyo Metropolitan Organization For Medical Research Highly functional enzyme having α-galactosidase activity
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
JP5364382B2 (ja) 2006-02-07 2013-12-11 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 遊離チオール部分を有するタンパク質の安定化された組成物
ES2697502T3 (es) 2006-02-09 2019-01-24 Genzyme Corp Administración intraventricular lenta
WO2008143354A1 (ja) * 2007-05-18 2008-11-27 Tokyo Metropolitan Organization For Medical Research 酵素補充療法用医薬組成物
CN105879047A (zh) 2008-12-16 2016-08-24 建新公司 寡糖-蛋白缀合物
RU2733466C2 (ru) 2009-07-28 2020-10-01 Шайр Хьюман Дженетик Терапиз Композиции и способы для лечения болезни гоше
CA2796607C (en) 2010-04-23 2019-09-10 Synageva Biopharma Corp Lysosomal storage disease enzyme
WO2012012461A2 (en) 2010-07-19 2012-01-26 Shire Human Genetic Therapies, Inc. Mannose receptor c type 1 (mrc1) codon optimized cell line and uses thereof
AU2011314293B2 (en) 2010-09-09 2015-06-04 Alexion Pharmaceuticals, Inc. Use of Lysosomal Acid Lipase for treating Lysosomal Acid Lipase Deficiency in patients
KR20140006037A (ko) 2011-02-15 2014-01-15 시나게바 바이오파르마, 코포레이션 리소좀의 산 리파제 결핍을 치료하는 방법들
SI2773438T2 (sl) * 2011-11-02 2022-05-31 F.Hoffmann-La Roche Ag Izpiralna kromatografija s preobremenitvijo
US9623090B2 (en) 2012-03-02 2017-04-18 Shire Human Genetic Therapies, Inc. Compositions and methods for treating type III gaucher disease
BR112014032919B1 (pt) * 2012-06-29 2023-03-28 Universitat De Barcelona Conjugado e seu método de produção, lipossomas, uso e método de produção dos mesmos, bem como composição farmacêutica
WO2014016873A1 (en) * 2012-07-26 2014-01-30 Jcr Pharmaceuticals Co., Ltd. Method for production of recombinant human alpha-galactosidase a
JP6226435B2 (ja) * 2012-07-26 2017-11-08 Ｊｃｒファーマ株式会社 組換えヒトα−ガラクトシダーゼＡの製造方法
WO2014066471A1 (en) 2012-10-24 2014-05-01 Genzyme Corporation Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers
TWI793159B (zh) 2013-10-23 2023-02-21 美商健臻公司 重組醣蛋白及其用途
EP4234699A1 (en) 2014-12-22 2023-08-30 Codexis, Inc. Human alpha-galactosidase variants
WO2016116966A1 (en) 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
CN116270739A (zh) 2017-06-30 2023-06-23 富士胶片株式会社 细胞结构体在制造溶酶体贮积病处置剂中的用途
ES2716305B2 (es) 2017-12-11 2019-11-27 Fund Biomedica Galicia Sur Uso de chaperonas farmacologicas para el tratamiento de enfermedades de deposito lisosomal
AU2019403323A1 (en) 2018-12-20 2021-07-01 Codexis, Inc. Human alpha-galactosidase variants
CN111308095A (zh) * 2020-03-04 2020-06-19 北京师范大学 用于诊断前列腺癌的尿液蛋白标记物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2619719B1 (fr) * 1987-09-01 1991-05-10 Sanofi Sa Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
DE3887425T2 (de) * 1987-10-02 1994-06-23 Zymogenetics Inc BAR1-Sekretions-Signal-Sequenz.
WO1990011353A1 (en) * 1989-03-24 1990-10-04 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
NZ234453A (en) * 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
CA2022983A1 (en) * 1989-08-11 1991-02-12 Mei-Huei Lai Expression of a functional insect specific toxin gene in mammalian cells
CA2092823A1 (en) * 1990-09-28 1992-03-29 Barry D. Greenberg Transgenic animals with alzheimer's amyloid precursor gene
US5356804A (en) 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
CA2098599A1 (en) * 1991-10-16 1993-04-17 William F. Swain Particle-mediated transformation of animal somatic cells
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
NZ245015A (en) * 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
SE9300105D0 (sv) * 1993-01-15 1993-01-15 Kabi Pharmacia Ab Stable protein solution
EP0726944B1 (en) * 1993-07-02 2002-12-18 Incyte Pharmaceuticals, Inc. Glycosylated and non-glycosylated bactericidal/permeability increasing proteins, and methods for producing same
ES2260568T3 (es) 1994-01-13 2006-11-01 The Rogosin Institute Celulas secretoras macroencapsuladas.
JP2984552B2 (ja) * 1994-09-02 1999-11-29 大和化成株式会社 ラッカーゼおよびその生産方法
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
JPH08196293A (ja) * 1995-01-25 1996-08-06 Mitsui Toatsu Chem Inc タンパク質の製造方法
ATE323724T1 (de) * 1995-02-15 2006-05-15 Amgen Inc Mpl-liganden analoga

Also Published As

Publication number Publication date
PL332188A1 (en) 1999-08-30
NO991225L (no) 1999-05-10
DE69732129D1 (de) 2005-02-03
AU4424497A (en) 1998-04-02
IL184637A (en) 2015-07-30
JP2007289201A (ja) 2007-11-08
NO328443B1 (no) 2010-02-22
KR20050084473A (ko) 2005-08-26
JP2012019793A (ja) 2012-02-02
JP4313381B2 (ja) 2009-08-12
JP5590788B2 (ja) 2014-09-17
ES2234032T3 (es) 2005-06-16
HU227189B1 (en) 2010-10-28
CA2265464C (en) 2007-06-26
WO1998011206A2 (en) 1998-03-19
EP2327775A2 (en) 2011-06-01
JP2009102321A (ja) 2009-05-14
DK1538202T3 (en) 2014-03-24
JP2001504324A (ja) 2001-04-03
NO991225D0 (no) 1999-03-12
ES2458292T3 (es) 2014-04-30
HK1022173A1 (en) 2000-07-28
NZ506214A (en) 2002-11-26
JP4313405B2 (ja) 2009-08-12
JP2007000145A (ja) 2007-01-11
EP1538202A2 (en) 2005-06-08
KR20000036078A (ko) 2000-06-26
JP2009060918A (ja) 2009-03-26
DK2374876T3 (en) 2016-05-30
HU1000445D0 (en) 2010-11-29
NO20110496L (no) 1999-05-10
WO1998011206A3 (en) 1998-08-13
MX340738B (es) 2016-07-22
HK1074058A1 (en) 2005-10-28
CN1268741C (zh) 2006-08-09
TW585919B (en) 2004-05-01
NO330687B1 (no) 2011-06-06
EP2327775A3 (en) 2012-10-24
EP0935651A2 (en) 1999-08-18
EP2374876A3 (en) 2012-10-24
NO20090583L (no) 1999-05-10
EP1538202A3 (en) 2007-05-30
NO20141168L (no) 1999-05-10
JP4001925B2 (ja) 2007-10-31
ES2581828T3 (es) 2016-09-07
RU2179034C2 (ru) 2002-02-10
CN1230220A (zh) 1999-09-29
PL190041B1 (pl) 2005-10-31
IL184637A0 (en) 2009-09-22
CA2265464A1 (en) 1998-03-19
HUP9904666A3 (en) 2001-09-28
IL128960A0 (en) 2000-02-17
EP2374876B1 (en) 2016-04-13
NO340408B1 (no) 2017-04-18
NZ334721A (en) 2001-01-26
HK1162580A1 (zh) 2012-08-31
KR100547402B1 (ko) 2006-02-01
JP2015044830A (ja) 2015-03-12
DE69732129T2 (de) 2005-12-08
HU9904666A (en) 2000-05-28
HU230275B1 (hu) 2015-11-30
IL128960A (en) 2007-10-31
EP2374876A2 (en) 2011-10-12
ATE286120T1 (de) 2005-01-15
EP1538202B1 (en) 2014-01-22
EP0935651B1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
PT1538202E (pt) Produção de alga-galactosidase a humana
ZA966507B (en) Process for the production of epoxides from olefins.
HU9603503D0 (en) Process for producing olefins
HU9602820D0 (en) Process for decomposing of cycloalkyl hydroperoxide
IL147575A0 (en) Method for purifying keratinocyte growth factors
EP0603671A3 (de) Verfahren zur Reaktivierung von gereinigten Membranproteinen.
IL128028A0 (en) Treatment of psychotic disorders
EP0604092A3 (en) Improved process for the production of alkyl halosilanes.
EP0682034A3 (en) Process for the preparation of cyanoalkylorganooxysilanes from cyanoalkylchlorosilanes.
WO1997035015A3 (de) Tyrosin-phosphatase-verwandtes protein
GR3005080T3 (pt)
AU4106396A (en) Process for performing retro-aldol reaction
MX9604599A (es) Procedimiento para la sintesis enzimatica de nucleotido-6-desoxi-d-xilo-4-hexulosas.
EP0795542A4 (en) PROCESS FOR PRODUCING ACRYLONITRILE DIMERS
EP0630970A3 (en) Process for the preparation of canthaxanthin.
SI0813597T1 (sl) Postopek za ciscenje od vitamina K odvisnih koagulacijskih faktorjev s kromatografijo
HU913531D0 (en) Process for the production of leather treating substance from environment-damaging, protein containing sewage
IL112698A (en) Displacement chromatography process for purification of hemoglobin
WO1998056822A3 (en) Process for the separation of specific immunoglobulins from standard plasma
ZA967336B (en) Process for the recovery of gold
FI963244A (fi) Menetelmä 2-butyyli-2-etyyli-1,3-propaanidiolin erottamiseksi sitä sisältävistä reaktioseoksista
HU9200787D0 (en) Process for the production of fish-foods from protein waste